As Applied Biosystems' acquisition of Ambion nears completion, a cancer diagnostics start-up being created out of the diagnostics and services divisions of Ambion not included in the buy-out is expected to be fully ramped up by mid-year, according to founder Matt Winkler.

The new company, Asuragen, has also inked a deal that will maintain the ties Ambion had established with Rosetta Genomics, an Israeli company developing microRNA-based diagnostics and therapeutics, Winkler told RNAi News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.